111 related articles for article (PubMed ID: 30910803)
1. MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma.
Kim E; Zucconi BE; Wu M; Nocco SE; Meyers DJ; McGee JS; Venkatesh S; Cohen DL; Gonzalez EC; Ryu B; Cole PA; Alani RM
Cancer Res; 2019 May; 79(10):2649-2661. PubMed ID: 30910803
[TBL] [Abstract][Full Text] [Related]
2. Acetylation reprograms MITF target selectivity and residence time.
Louphrasitthiphol P; Loffreda A; Pogenberg V; Picaud S; Schepsky A; Friedrichsen H; Zeng Z; Lashgari A; Thomas B; Patton EE; Wilmanns M; Filippakopoulos P; Lambert JP; Steingrímsson E; Mazza D; Goding CR
Nat Commun; 2023 Sep; 14(1):6051. PubMed ID: 37770430
[TBL] [Abstract][Full Text] [Related]
3. pH-controlled histone acetylation amplifies melanocyte differentiation downstream of MITF.
Raja DA; Gotherwal V; Burse SA; Subramaniam YJ; Sultan F; Vats A; Gautam H; Sharma B; Sharma S; Singh A; Sivasubbu S; Gokhale RS; Natarajan VT
EMBO Rep; 2020 Jan; 21(1):e48333. PubMed ID: 31709752
[TBL] [Abstract][Full Text] [Related]
4. p300 KAT regulates SOX10 stability and function in human melanoma.
Waddell A; Grbic N; Leibowitz K; Wyant WA; Choudhury S; Park K; Collard M; Cole PA; Alani RM
bioRxiv; 2024 Feb; ():. PubMed ID: 38469149
[TBL] [Abstract][Full Text] [Related]
5. HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis.
Emmons MF; Bennett RL; Riva A; Gupta K; Carvalho LADC; Zhang C; Macaulay R; Dupéré-Richér D; Fang B; Seto E; Koomen JM; Li J; Chen YA; Forsyth PA; Licht JD; Smalley KSM
Nat Commun; 2023 Nov; 14(1):7759. PubMed ID: 38030596
[TBL] [Abstract][Full Text] [Related]
6. Novel berberine derivatives as p300 histone acetyltransferase inhibitors in combination treatment for breast cancer.
Lai R; Lin Z; Yang C; Hai L; Yang Z; Guo L; Nie R; Wu Y
Eur J Med Chem; 2024 Feb; 266():116116. PubMed ID: 38215590
[TBL] [Abstract][Full Text] [Related]
7. Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300/CBP inhibition.
Shendy NAM; Bikowitz M; Sigua LH; Zhang Y; Mercier A; Khashana Y; Nance S; Liu Q; Delahunty IM; Robinson S; Goel V; Rees MG; Ronan MA; Wang T; Kocak M; Roth JA; Wang Y; Freeman BB; Orr BA; Abraham BJ; Roussel MF; Schonbrunn E; Qi J; Durbin AD
Nat Commun; 2024 Apr; 15(1):3483. PubMed ID: 38664416
[TBL] [Abstract][Full Text] [Related]
8. MITF regulates IDH1 and NNT and drives a transcriptional program protecting cutaneous melanoma from reactive oxygen species.
Roider E; Lakatos AIT; McConnell AM; Wang P; Mueller A; Kawakami A; Tsoi J; Szabolcs BL; Ascsillán AA; Suita Y; Igras V; Lo JA; Hsiao JJ; Lapides R; Pál DMP; Lengyel AS; Navarini A; Okazaki A; Iliopoulos O; Németh I; Graeber TG; Zon L; Giese RW; Kemeny LV; Fisher DE
bioRxiv; 2023 Nov; ():. PubMed ID: 38014031
[TBL] [Abstract][Full Text] [Related]
9. Super-enhancer-driven expression of BAHCC1 promotes melanoma cell proliferation and genome stability.
Berico P; Nogaret M; Cigrang M; Lallement A; Vand-Rajabpour F; Flores-Yanke A; Gambi G; Davidson G; Seno L; Obid J; Vokshi BH; Le Gras S; Mengus G; Ye T; Cordero CF; Dalmasso M; Compe E; Bertolotto C; Hernando E; Davidson I; Coin F
Cell Rep; 2023 Nov; 42(11):113363. PubMed ID: 37924516
[TBL] [Abstract][Full Text] [Related]
10. Significant and Various Effects of ML329-Induced MITF Suppression in the Melanoma Cell Line.
Nishikiori N; Watanabe M; Sato T; Furuhashi M; Okura M; Hida T; Uhara H; Ohguro H
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254754
[TBL] [Abstract][Full Text] [Related]
11. Unravelling the Role of P300 and TMPRSS2 in Prostate Cancer: A Literature Review.
Gioukaki C; Georgiou A; Gkaralea LE; Kroupis C; Lazaris AC; Alamanis C; Thomopoulou GE
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511059
[TBL] [Abstract][Full Text] [Related]
12. Chromosome instability-associated prognostic signature and cluster investigation for cutaneous melanoma cases.
Liu N; Liu G; Ma Q; Li X
IET Syst Biol; 2023 Jun; 17(3):121-130. PubMed ID: 37186446
[TBL] [Abstract][Full Text] [Related]
13. Effects of the Acetyltransferase p300 on Tumour Regulation from the Novel Perspective of Posttranslational Protein Modification.
Zeng Q; Wang K; Zhao Y; Ma Q; Chen Z; Huang W
Biomolecules; 2023 Feb; 13(3):. PubMed ID: 36979352
[TBL] [Abstract][Full Text] [Related]
14. KATs off: Biomedical insights from lysine acetyltransferase inhibitors.
Whedon SD; Cole PA
Curr Opin Chem Biol; 2023 Feb; 72():102255. PubMed ID: 36584580
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies.
Rubanov A; Berico P; Hernando E
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497341
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases.
Gibson F; Hanly A; Grbic N; Grunberg N; Wu M; Collard M; Alani RM
Clin Rev Allergy Immunol; 2022 Dec; 63(3):447-471. PubMed ID: 36346551
[TBL] [Abstract][Full Text] [Related]
17. Advanced Acral Melanoma Therapies: Current Status and Future Directions.
Zhang Y; Lan S; Wu D
Curr Treat Options Oncol; 2022 Oct; 23(10):1405-1427. PubMed ID: 36125617
[TBL] [Abstract][Full Text] [Related]
18. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents.
Chen Q; Yang B; Liu X; Zhang XD; Zhang L; Liu T
Theranostics; 2022; 12(11):4935-4948. PubMed ID: 35836809
[TBL] [Abstract][Full Text] [Related]
19. MITF in Normal Melanocytes, Cutaneous and Uveal Melanoma: A Delicate Balance.
Gelmi MC; Houtzagers LE; Strub T; Krossa I; Jager MJ
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682684
[TBL] [Abstract][Full Text] [Related]
20. Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations.
Shi Q; Liu L; Chen J; Zhang W; Guo W; Wang X; Wang H; Guo S; Yue Q; Ma J; Liu Y; Zhu G; Zhao T; Zhao J; Liu Y; Gao T; Li C
Clin Cancer Res; 2022 Jun; 28(12):2690-2703. PubMed ID: 35294533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
